Farnesoid X receptor agonism – a new approach to the treatment of cholesterol gallstone disease

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.4, 2005-04, pp. : 535-538

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment

Current Medicinal Chemistry, Vol. 17, Iss. 2, 2010-01 ,pp. : 139-159

Bentham Science Publishers

Access to resources Recommend Favorite

Modulation of Cholesterol Crystallization in Bile. Implications for Non- Surgical Treatment of Cholesterol Gallstone Disease

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 5, Iss. 2, 2005-06 ,pp. : 177-184

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Reflections in Cholesterol Homeostasis and Gallstone Disease: A Review

Current Medicinal Chemistry, Vol. 21, Iss. 12, 2014-04 ,pp. : 1435-1447

Bentham Science Publishers

Access to resources Recommend Favorite

Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 9, 2011-08 ,pp. : 753-762

Bentham Science Publishers

Access to resources Recommend Favorite

Hologram QSAR Studies on Farnesoid X Receptor Activators

Letters in Drug Design & Discovery, Vol. 3, Iss. 4, 2006-05 ,pp. : 261-267

Bentham Science Publishers

Access to resources Recommend Favorite